Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 14/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928147 | 0.86 | PDGFRB (0.58) | HPGDSPDGFRBPDGFRAEGFRNCF1 | |
| SCHEMBL28808959 | 0.83 | HPGDS (0.65) | HPGDSPDGFRBPDGFRAEGFRNCF1 | |
| SCHEMBL6033827 | 0.80 | HPGDS (0.61) | HPGDSPDGFRBPDGFRAEGFRNCF1 | |
| SCHEMBL18572654 | 0.79 | HPGDS (0.59) | HPGDSPDGFRBPDGFRAEGFRNCF1 | |
| SCHEMBL13356641 | 0.79 | HPGDS (0.59) | HPGDSPDGFRBPDGFRAEGFRNCF1 | |
| SCHEMBL1069738 | 0.79 | HPGDS (0.59) | HPGDSPDGFRBPDGFRAEGFRNCF1 | |
| SCHEMBL18572655 | 0.79 | HPGDS (0.59) | HPGDSPDGFRBPDGFRAEGFRNCF1 | |
| SCHEMBL4371627 | 0.79 | HPGDS (0.59) | HPGDSPDGFRBPDGFRAEGFRNCF1 | |
| SCHEMBL23980622 | 0.77 | HPGDS (0.58) | HPGDSPDGFRBPDGFRAEGFRNCF1 | |
| SCHEMBL3014652 | 0.77 | PDGFRB (0.79) | HPGDSPDGFRBPDGFRAEGFRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150980-B1 | 16-HALOGEN-EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AG (DE) | 2007-08-22 | — | — | EP | claimed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2261223-B1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8217035-B2 | Pyrimidine derivatives used as PI-3-kinase inhibitors | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| EP-2261223-A1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1984350-B1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-08-18 | — | — | EP | disclosed |
| EP-1984350-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-20070225318-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | BIOLIPOX AB (SE) | 2007-09-27 | — | — | US | disclosed |
| EP-1150980-B1 | 16-HALOGEN-EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| EP-1794145-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032851-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225318-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | ALOX15, ALOX15B, ALOX12 | HPGDS 56/4885PDGFRB 1848/4885PDGFRA 2096/4885 |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | HPGDS 92/4885PDGFRB 389/4885PDGFRA 464/4885 |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | HPGDS 662/4885PDGFRB 512/4885PDGFRA 560/4885 |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | HPGDS 642/4885PDGFRB 460/4885PDGFRA 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.